Schering-Plough's synthetic hormone Livial significantly increases the risk of breast cancer recurrence in patients who had tumors removed, according to a Dutch study. Researchers advised doctors to stop prescribing the drug to breast cancer patients. A spokeswoman for Schering-Plough said the company was aware of the data and never promoted the drug for breast cancer patients.

Full Story:

Related Summaries